BioCentury
ARTICLE | Top Story

Sanofi's pick checks boxes in emerging markets, established products

February 21, 2015 1:42 AM UTC

Investors had a muted response to the appointment of Olivier Brandicourt as the new CEO at Sanofi (Euronext:SAN; NYSE:SNY), as the pharma's shares shed EUR 0.45 to EUR 87.39 on Euronext and were unchanged at $50.10 on NYSE on Friday, the day after the pharma announced he would take over on April 2.

Following the executive suite blowup between ousted chief executive Christopher Viehbacher and Chairman Serge Weinberg, shareholders will be seeking visibility on how Brandicourt plans to restore growth in the pivotal U.S. diabetes market, and how he oversees the launch of key pipeline products like Praluent alirocumab for hypercholesterolemia, which is partnered with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Praluent is under EMA review and has a July 24 PDUFA date in the U.S. ...